

Company Overview

Monopar Therapeutics is an emerging biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. Monopar currently has three compounds in development: Validive® (clonidine mucobuccal tablet; clonidine MBT), a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis (SOM) in patients undergoing radiotherapy for oropharyngeal cancer (OPC); MNPR-201 (formerly GPX-150), a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs; and MNPR-101 (formerly huATN-658), a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers.

Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on \$9.7M in Financing, and Filing of Form 10 Registration Statement

Nov 14 2017, 10:40 AM EST

Monopar Therapeutics Announces Partnership With Cancer Research UK And Cancer Research Technology To Develop New Oncology Compound

Jul 9 2015, 11:58 AM EDT

Management Team

Chandler D. Robinson, MD MBA MSc
Co-Founder and Chief Executive Officer

Christopher M. Starr, PhD
Co-Founder and Executive Chairman

Andrew P. Mazar, PhD
Co-Founder and Executive Vice President, Research and Development
Chief Scientific Officer

Kim R. Tsuchimoto
Chief Financial Officer

Patrice Rioux, MD, PhD
Acting Chief Medical Officer

Monopar Therapeutics Inc.

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.